Comparable stake leader
GMS Ventures & Investments
SEC ownership of Outlook Therapeutics, Inc.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001649989.
Disclosed value leader
GMS Ventures & Investments
Comparable rows
50/50
Latest evidence
12 Aug 2026
- Public ticker
- OTLK on Nasdaq
- Parsed ownership sources
-
13D/G, 3/4/5, and 13F
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
GMS Ventures & Investments
Ranking: Comparable ownership first, then disclosed value
- Comparable ownership rows
-
50 of 50
Meaning: Rows with safely comparable ownership %
- Latest 13D/G holder
-
GMS Ventures & Investments
Source: Latest parsed Schedule 13D/G stake
- Latest parsed ownership date
-
12 Aug 2026
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0001649989
- Issuer location
- Iselin, NJ
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
3 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of Outlook Therapeutics, Inc. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
GMS Ventures & Investments
Disclosed value leader
GMS Ventures & Investments
Comparable rows
50/50
Latest evidence
12 Aug 2026
13D/G
3/4/5
13F
Lead comparable stake: 16%
13D/G row: GMS Ventures & Investments
Showing 1-8 of 50 holder rows.
Quick read
GMS Ventures & Investments leads the comparable SEC ownership view at 16%.
50 of 50 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens GMS Ventures & Investments's linked filing trail.
Comparable ownership
Top 5
GMS Ventures & Investments
16%
CVI Investments, Inc.
9.9%
TANG CAPITAL PARTNERS LP
6.4%
GREAT POINT PARTNERS LLC
5%
Empery Asset Management, LP
5%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 50 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| GMS Ventures & Investments |
13D/G
3/4/5
Director, 10%+ Owner
|
16%
|
$66,078,270
42,631,142 shares
|
+$7,828,281 | 12 Aug 2026 |
| CVI Investments, Inc. |
13D/G
|
9.9%
|
$24,713,908
24,713,908 shares
|
$0 | 12 Aug 2026 |
| TANG CAPITAL PARTNERS LP |
13D/G
TANG CAPITAL MANAGEMENT, LLC
|
6.4%
|
$2,624,703
1,682,502 shares
|
$0 | 31 Dec 2024 |
| GREAT POINT PARTNERS LLC |
13D/G
|
5%
|
$4,484,400
2,220,000 shares
|
$0 | 30 Jun 2025 |
| Empery Asset Management, LP |
13D/G
|
5%
|
$2,472,925
2,332,948 shares
|
-$914,455 | 30 Sep 2025 |
| INTRACOASTAL CAPITAL, LLC |
13D/G
Mitchell P. Kopin
|
5%
|
$1,232,834
5,990,447 shares
|
$0 | 22 Apr 2026 |
| SPHERA FUNDS MANAGEMENT LTD. |
13D/G
|
4.7%
|
$4,983,092
3,153,856 shares
|
+$920,239 | 31 Dec 2025 |
| TANG CAPITAL MANAGEMENT LLC |
13D/G
|
3.4%
|
$3,030,000
1,500,000 shares
|
-$808,000 | 30 Jun 2025 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Net insider flow leans to buying over the last 12 months. Net value: +$15,343,625.
Buys
$15,343,625
Insiders: 6
Sells
$0
Insiders: 0
Net
+$15,343,625
Shares: +22,786,494
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 22,786,494
Shares: 0
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 5,145,902 | 0 | $5,099,995 | $0 | +$5,099,995 |
| 3-6 | 17,640,592 | 0 | $10,243,630 | $0 | +$10,243,630 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-19 of 19 reporting-owner rows connected to Outlook Therapeutics, Inc.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
19
Largest Forms 3/4/5 holder
Tenshi Healthcare Pte. Ltd.
Net 12M change
+$15,343,625
Latest report
01 Sep 2026
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Tenshi Healthcare Pte. Ltd. | 10%+ Owner | $26,085,170 | Mixed | 21 Apr 2022 | ||
| Arun Kumar Pillai | Director, 10%+ Owner | $26,085,170 | Mixed | 01 Feb 2022 | ||
| Sukhtian Ghiath M. | Director, 10%+ Owner | $24,371,146 | +$7,499,999 | +44% | Filing P/S | 12 Aug 2026 |
| GMS Ventures & Investments | Director, 10%+ Owner | $24,371,146 | +$7,499,999 | +44% | Filing P/S | 12 Aug 2026 |
| Terry Dagnon | Chief Operations Officer | $741,221 | Filing P/S | 20 Apr 2023 | ||
| Syntone Ventures LLC | 10%+ Owner | $716,284 | Mixed | 15 Apr 2024 | ||
| Jeff Evanson | Chief Commercial Officer | $339,553 | Filing P/S | 20 Mar 2024 | ||
| Robert Charles Jahr | Chief Executive Officer, Director | $240,908 | Median | 14 Aug 2026 | ||
| Faisal Ghiath Sukhtian | Director | $231,622 | +$150,002 | +184% | Filing P/S | 29 Jul 2026 |
| Kurt J. Hilzinger | Director | $186,958 | +$176,520 | +1691% | Filing P/S | 26 May 2026 |
| Lawrence A. Kenyon | Chief Financial Officer, Director | $170,060 | Median | 14 Aug 2026 | ||
| Yezan Munther Haddadin | Director | $13,617 | +$14,960 | +110% | Mixed | 02 Jun 2026 |
| Randy H. Thurman | Director | $2,399 | +$2,145 | +844% | Filing P/S | 26 May 2026 |
| Kevin Michael Lundquist | Chief Financial Officer | Mixed | 01 Sep 2026 | |||
| Julian S. Gangolli | Director | Mixed | 01 Oct 2025 | |||
| C. Russell Trenary III | CEO AND PRESIDENT, Director | Mixed | 20 Mar 2024 | |||
| Gerd Auffarth | Director | Mixed | 01 Oct 2025 | |||
| Julia A. Haller | Director | Mixed | 01 Oct 2025 | |||
| Andong Huang | Director | Mixed | 01 Oct 2025 |
Recent insider transactions for Outlook Therapeutics, Inc.
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Kevin Michael Lundquist | OTLK | Employee Stock Option (Right to Buy) | Award | 500,000 | 500,000 | 01 Sep 2026 | Direct | |||
| Robert Charles Jahr | OTLK | Common Stock | Purchase | 151,515 | 151,515 | 14 Aug 2026 | Direct | |||
| Robert Charles Jahr | OTLK | Warrants (right to buy) | Purchase | 151,515 | 151,515 | 14 Aug 2026 | Direct | |||
| Lawrence A. Kenyon | OTLK | Common Stock | Purchase | 1698.8% | 101,010 | 106,956 | 14 Aug 2026 | Direct | ||
| Lawrence A. Kenyon | OTLK | Warrants (right to buy) | Purchase | 101,010 | 101,010 | 14 Aug 2026 | Direct | |||
| Sukhtian Ghiath M. | OTLK | Common Stock | Purchase | 11.4% | $2,499,999 | $0.9900 | 2,525,252 | 24,617,320 | 12 Aug 2026 | See footnote |
| Ghiath M. Sukhtian | OTLK | Common Stock | Purchase | 11.4% | $2,499,999 | $0.9900 | 2,525,252 | 24,617,320 | 12 Aug 2026 | See footnote |
| Sukhtian Ghiath M. | OTLK | Warrants (right to buy) | Purchase | 2,525,252 | 2,525,252 | 12 Aug 2026 | See footnote | |||
| Ghiath M. Sukhtian | OTLK | Warrants (right to buy) | Purchase | 2,525,252 | 2,525,252 | 12 Aug 2026 | See footnote | |||
| Faisal Ghiath Sukhtian | OTLK | Common Stock | Purchase | 76% | $99,996 | $1.05 | 95,398 | 220,972 | 29 Jul 2026 | Direct |
| Lawrence A. Kenyon | OTLK | Stock Option (Right to Buy) | Award | 210,078 | 210,078 | 21 Jul 2026 | Direct | |||
| Robert Charles Jahr | OTLK | Stock Option (Right to Buy) | Award | 100,000 | 100,000 | 21 Jul 2026 | Direct | |||
| Yezan Munther Haddadin | OTLK | Common Stock | Purchase | 78% | 29,000 | 66,167 | 02 Jun 2026 | Direct | ||
| Sukhtian Ghiath M. | OTLK | Common Stock | Purchase | 63% | $5,000,000 | $0.5855 | 8,539,709 | 22,092,068 | 28 May 2026 | See footnote |
| Ghiath M. Sukhtian | OTLK | Common Stock | Purchase | 63% | $5,000,000 | $0.5855 | 8,539,709 | 22,092,068 | 28 May 2026 | See footnote |
| Sukhtian Ghiath M. | OTLK | Warrants (right to buy) | Purchase | 15,488,570 | 8,571,428 | 28 May 2026 | See footnote | |||
| Ghiath M. Sukhtian | OTLK | Warrants (right to buy) | Purchase | 15,488,570 | 8,571,428 | 28 May 2026 | See footnote | |||
| Sukhtian Ghiath M. | OTLK | Warrants (right to buy) | Expiration (or cancellation) of long derivative position with value received | -100% | -15,488,570 | 0 | 28 May 2026 | See footnote | ||
| Ghiath M. Sukhtian | OTLK | Warrants (right to buy) | Expiration (or cancellation) of long derivative position with value received | -100% | -15,488,570 | 0 | 28 May 2026 | See footnote | ||
| Faisal Ghiath Sukhtian | OTLK | Common Stock | Purchase | 3593.4% | $50,006 | $0.4093 | 122,174 | 125,574 | 27 May 2026 | Direct |
| Yezan Munther Haddadin | OTLK | Common Stock | Purchase | 1073.6% | $14,960 | $0.4400 | 34,000 | 37,167 | 26 May 2026 | Direct |
| Randy H. Thurman | OTLK | Common Stock | Purchase | 843.2% | $2,145 | $0.4290 | 5,000 | 5,593 | 26 May 2026 | Direct |
| Kurt J. Hilzinger | OTLK | Common Stock | Purchase | 1691% | $176,520 | $0.4413 | 400,000 | 423,655 | 26 May 2026 | Direct |
| Andong Huang | OTLK | Stock Option (Right to Buy) | Award | 53,316 | 53,316 | 03 Oct 2025 | Direct | |||
| Julia A. Haller | OTLK | Stock Option (Right to Buy) | Award | 58,648 | 58,648 | 03 Oct 2025 | Direct | |||
| Kurt J. Hilzinger | OTLK | Stock Option (Right to Buy) | Award | 90,638 | 90,638 | 03 Oct 2025 | Direct | |||
| Yezan Munther Haddadin | OTLK | Stock Option (Right to Buy) | Award | 95,969 | 95,969 | 03 Oct 2025 | Direct | |||
| Gerd Auffarth | OTLK | Stock Option (Right to Buy) | Award | 58,648 | 58,648 | 03 Oct 2025 | Direct | |||
| Faisal Ghiath Sukhtian | OTLK | Stock Option (Right to Buy) | Award | 117,296 | 117,296 | 03 Oct 2025 | Direct | |||
| Andong Huang | OTLK | Stock Option (Right to Buy) | Award | 286,734 | 286,734 | 01 Oct 2025 | Direct | |||
| Julia A. Haller | OTLK | Stock Option (Right to Buy) | Award | 286,734 | 286,734 | 01 Oct 2025 | Direct | |||
| Kurt J. Hilzinger | OTLK | Stock Option (Right to Buy) | Award | 286,734 | 286,734 | 01 Oct 2025 | Direct | |||
| Julian S. Gangolli | OTLK | Stock Option (Right to Buy) | Award | 286,734 | 286,734 | 01 Oct 2025 | Direct | |||
| Yezan Munther Haddadin | OTLK | Stock Option (Right to Buy) | Award | 286,734 | 286,734 | 01 Oct 2025 | Direct | |||
| Gerd Auffarth | OTLK | Stock Option (Right to Buy) | Award | 286,734 | 286,734 | 01 Oct 2025 | Direct | |||
| Randy H. Thurman | OTLK | Stock Option (Right to Buy) | Award | 286,734 | 286,734 | 01 Oct 2025 | Direct | |||
| Faisal Ghiath Sukhtian | OTLK | Stock Option (Right to Buy) | Award | 286,734 | 286,734 | 01 Oct 2025 | Direct |
* marks a reported price that did not pass the local price check.